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INTRODUCTION
The intra uterine device is one of the most widely used methods 
of family planning with more than Seventy Million users world wide. 
The  first  generation are non-medicated  devices includes  lippes  loop 
and coil devices used in 1960 and the second generation are medicated 
devices  include  copper  used  in  late  60  and  progesterone  releasing 
devices.  I.U.C.D.  insanideal  temporary contraceptive.  It  is  effective, 
safe and has no systemic effects, even the para medical personnel can 
be trained for  selecting  counseling and insertion.  The women using 
I.U.C.D. is more safer, more convenient, more effective in preventing 
pregnancy than condom, spermicide and any other barrier methods.
Recent research is helping to lift a cloud that has hung over the 
I.U.C.D. for the past several years. Research has shown that I.U.C.d. 
use increases the risk of pelvic inflammatory disease and subsequently 
infertility. Newer studies and new analysis of earlier studies, show that 
the risk of  infection is largely limited to the first  four months after 
I.U.C.D.  insertion  and  to  women  exposed  to  sexually  transmitted 
diseases. There appears to be virtually no increased risk of infertility in 
a  woman  using  a  copper  IUD  who  has  a  mutually  faithful  sexual 
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relationship  with  one  partner  and  thus  is  not  exposed  to  sexually 
transmitted diseases.
Similarly, evidence shows that copper and all plastic IUDs do 
not  increase  the  risk  of  ectopic  pregnancies.  In  fact,  these  IUDs 
provide some protection against  them. This finding helps to settle a 
long standing debate. (Population Reports, Series B, 5th March’88).
Successful I.U.C.D. use depends upon (1) use of well designed 
and tested I.U.C.D.
2) Careful screening of the women
3) Women who has S.T.D. should not use I.U.C.D.
4) Careful  insertion  carried  out  under  sterile  condition  with 
disinfected instruments that places IUD high in uterus. This 
will minimize the pain during insertion, risk of perferation, 
infection, and chances of pregnancy and expulsion. An IUD, 
can  be  inserted  at  any  time  during  the  menstrual  cycle 
provided the pregnancy is ruled out. 
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5) Informative and sympathetic counseling. An IUD user needs 
to know and remember what signs call for medical attention, 
when  a  copper  or  hormone  –  releasing  IUD   should  be 
replaced, and that the IUD does not protect against A.I.D.S. 
and other sexually transmitted diseases. 
6) Regular  follow-up plus quick access to medical  care.  Help 
should be available quickly at any time an IUD user notices 
any signs  of  complications  or  has  any  concerns.  Not  only 
doctors  but  also  nurses,  midwives,  and  other  health  care 
providers can safely insert IUD whatever their back grounds, 
all need special training in Pelvic examination and insertion 
technique and also in screening, counseling, and followup. 
11
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HISTORICAL OVERVIEW
Early International Intrauterine Devices
The first IUDs for women were developed in nineteenth-century 
Germany as variations of  vaginal  pessaries.  These  early  IUDs were 
rigid metal appliances that extended from the vagina or the extocervix 
through  the  cervical  canal  into  the  endometrium.  They  were 
multipurpose devices that  only indirectly acted as contraceptives.  In 
1902 Hollweg introduced a self-inserted pessary that extended into the 
uterus  and  that  was  intended  explicitly  for  contraception.  In  1909 
Richter  introduced a silkworm-catgut  ring with a  nickel  and bronze 
wire protruding through the cervical os. Although there is no written 
record of how the male partner responded to this metal protrusion at 
the top of the vaginal vault, Pust rapidly replaced the metal wire with 
catgut thread and added features of the old button-type pessary. Given 
that these devices were used by women in the days before antibiotics 
or nonsteroidal anti-inflammatory drugs (NSAIDs), their use quickly 
became  associated  with  serious  infections  and  significant  patient 
discomfort. These side effects created such an enduring negative image 
for  IUDs that when Grafenberg introduced the first  true IUD in the 
1920s, it was generally rejected by the medical community.
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Early Intrauterine Devices
Although several  investigators  continued to  create  metal  wire 
devices, most of the successful new IUDs were based on polyurethane 
frames  embedded  with  barium  sulfate  to  make  them  visible  on 
radiographs. Within a decade, several plastic devices, such as the S-
shaped  Lippes  Loop,  the  Tatum  T,  and  the  Safe-T-Coil,  were  in 
widespread use. 
In 1969, Zipper reported that copper had a profound impact on 
the endometrium. When Tatum wrapped a thin copper wire around the 
stem of his plastic IUD to create the Copper T200, the first-year typical 
failure rates decreased to 1.5% to 2%. In 1971 the Copper 7 IUD was 
introduced and found  favour  with  physicians  for  use  in  nulliparous 
adolescent  women  who  had  difficulty  successfully  using  oral 
contraceptive pills.
In the late 1960s, investigators at John Hopkins developed the 
Dalkon Shield – an all-plastic  device  with small  plastic  protrusions 
around its edges to help it adhere to the endometrium and reduce the 
risk  of  expulsion.  Clinical  trials  conducted  following  the  FDA 
regulations for devices (not drugs) revealed that the first-year failure 
rate was 1% - lower than the rate for any IUD available at the time.  
14
PATTERNS  OF  CONTRACEPTIVE  USE  IN  DIFFERENT 
REGIONS
15
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REVIEW OF LITERATURE
An off-quoted but poorly substantiated story described the first 
IUD as a stone or stones placed in the uterus of camels in North Africa, 
to prevent pregnancy during long caravan journey. One version of the 
story however, suggests that the stones were actually put in the vagina, 
making the methods more akin to a chatity belt  than an IUD. Over 
2500 years ago Hippocrates is credited with using a hollow lead tube to 
insert  pessaries  or  other  objects  into  human  uterus.  Casonova 
recommended  a  gold  ball;  and  as  recently  as  1950  one  woman 
apparently used her wedding ring as a do-it-yourself IUD. 
Cervicouterine  stem  pessaries  were  used  from  the  late 
Nineteenth Century. They were made from material as exotic as ivory, 
glass, ebony and diamond studded platinum and were used for many 
purposes including contraception. Some were shaped like collar, stud, 
or had V.Shaped flexible wings inserted into the lower uterine cavity. 
When the devices fractured, as they sometimes did, leaving just the 
intrauterine part in position, it was learnt that the latter (rather than the 
surface cap covering the external OS) was the contraceptive. The first 
completely intrauterine device designed specifically for contraception 
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was a ring made of silk worm gut, described by Dr.Ritcher of Braslaw. 
Later, silver wire was wound around the silkworm by Grafenberg and 
it is of interest that later version were made of German silver, an alloy 
which contains copper. Now made of coiled stainless steel, the design 
is still one of the most widely used in China. 
Many of the early devices were used as abortifacients as well as 
contraceptives, and the resultant haemorrhage and pelvic infection led 
to widespread condemnation by the medical profession. This retarded 
acceptance of the method, which was only really achieved in 1962 at 
the  first  International  Conference  of  IUDs  in  New York  City.  The 
Lippes  Loop  was  presented  to  this  conference  by  its  inventor,  and 
became the standard and now the Cu IUD became popular. 
Eur J Gen Pract. 2004 Sep; 10 (3) : 82-7. Related Articles 
complications  of  the  intrauterine  device  in  nulliparous  and  parous 
women. 
Department of General Practice and Social Medicine, University 
of Nijmegen.
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Objectives :
The  intrauterine  device  (IUD)  is  still  related  to  pelvic 
inflammatory  disease  (PID),  pregnancy,  expulsion,  perforation  and 
menstrual problems, particularly in nulliparous women. We aimed to 
study the complications  and symptoms of  the intrauterine device in 
general practice, particularly in nulliparous women. METHODS : We 
used a retrospective cohort study in four general practices participating 
in the Nijmegen Continuous Morbidity Registration. Selected women 
had  one  or  more  IUDs  inserted  between  1981  and  2000.  data  on 
complications, symptoms and removal of the IUD were obtained from 
the  medical  records.  RESULTS  :  461  women  were  included,  129 
nulliparous and 332 parous women. Users of copper IUDs had a rate of 
PID of 3.5 per 1000 women-years, rates of (ectopic) pregnancy of 0.6 
to 1.1% per year and rates of expulsion of 0 to 1.2% per year. Rates of 
expulsion for the levonorgestrel – releasing IUDs were 0 to 0.2% per 
year. Nulliparous women did not show more complications than parous 
women. Menstrual problems were frequent among users of copper and 
levonorgestrel - releasing IUDs. One third of the IUDs were removed 
within the first year after insertion. There was no significant excess of 
IUD  removal  among  nulliparous  women  compared  with  parous 
women.  Main  reasons  for  removal  were  ‘menstrual  problems’  and 
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‘contraception  no  longer  necessary’.  CONCLUSION :  Both  copper 
and  levonorgestrel  –  releasing  IUDs  are  sage  and  highly  effective 
contraceptives,  which  can  adequately  be  inserted  and  monitored  by 
general practitioners in nulliparous and parous women.
Reprod  Health  Matters.  2004  May;12  (23):  136-43.  Related 
Articles, Links
Intrauterine  contraceptive  devices  and  risk  of  pelvic 
inflammatory  disease  :  standard  of  care  in  high  STI  prevalence 
settings.
The intrauterine contraceptive device (IUD) is highly effective 
and cost-effective. IUD use is limited in some regions, however, due to 
concerns  about  increased  risk  of  pelvic  inflammatory  disease  (PID) 
and  subsequent  complications  such  as  infertility  and  ectopic 
pregnancy. Recent reviews suggest that the overall risk of PID with 
modern IUDs is lower than previously thought, at least in regions with 
a low prevalence of sexually transmitted infections (STIs). Risk of PID 
may be higher, however, in places where gonorrhoea and chlamydia 
are prevalent, where screening for STIs is limited and where aseptic 
conditions  for  insertion  are  difficult  to  ensure.  A  World  Health 
20
Organization   multi-centre  study  and  other  studies  have  confirmed 
regional differences in STI prevalence, and the WHO study established 
that PID risk is temporally related to IUD insertion procedures. Studies 
of  the effectiveness of antibiotic  due at  least  in part  to use of sub-
therapeutic regimens for pathogens commonly implicated in PID. In 
summary, the IUD can be safe and effective if inserted under aseptic 
conditions in women free of cervical infection. Further study is needed 
to define appropriate standards of care for IUD insertion where STI 
prevalence is high and ability to rule out infection is limited. Even with 
safe  insertion,  IUD promotion in areas of  high STI/HIV prevalence 
must  address women’s needs for dual protection from infection and 
unwanted pregnancy.
Contraception. 2004 Apr; 69(4) : 279-82. Related Articles.
Clinical outcomes of early postplacental insertion of intrauterine 
contraceptive  devices.  Celen  S,  Moroy  P,  Sucak  A,  Aktulay  A, 
Danisman  N.  Zekai  Tahir  Burak  Women  Health  Education  and 
Research Hospital, Ankara, Turkey. Sevkicelenhotmail.com
OBJECTIVES  :  To  assess  the  efficacy,  safety  and  thus, 
advantages  and  disadvantages,  of  early  postplacental  intrauterine 
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device (IUD) insertion. METHODS :  IUDs were inserted within 10 
min after  postplacental expulsion in term pregnancy both in vaginal 
and  cesarean  delivereies  via  a  ring  forceps.  Of  the  276  patients 
enrolled, 235 were included in the study. Recipients were scheduled 
for examination before hospital discharge and at 6 weeks, 6 months 
and  12  months  after  postplacental  insertion.  RESULTS  :  The 
percentages of women returning for a follow-up visit were 221 (94%), 
210(89%)  and  183  (78%)  at  6  weeks,  6  months  and  12  months, 
respectively.  Among  IUD acceptors,  74% of  the  cases  had  vaginal 
deliveries  and  26% had  cesaren  deliveries.  Continuation  rates  were 
relatively high, 87.6% and 76.3%, at 6 and 12 months, respectively, 
after  postplacental  insertion  of  IUD.  In  this  study,  the  1-year 
cumulative  expulsion  rate  with Tcu 380A device was  12.3% which 
may  be  regarded  as  a  standard  expulsion  rate  for  immediate 
postplacental  insertion of similar  models of IUDs. CONCLUSION : 
The  evidence from this  study suggests  that  immediate  postplacental 
insertion of CuT 380 models is an effective, useful, safe, convenient 
and low-cost procedure for early postpartum contraception.
22
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Types of intrauterine devices available 
The  copper  IUD  (ParaGardT  380A,  Ortho-McNeil 
Pharmaceuticals,  Raritan, NJ) is a T-shaped plyethylene device with 
380 mm2 of exposed surface area of copper on its arms and stem. The 
polyethylene  frame  also  contains  barium  sulfate,  which  renders  it 
radiopaque.  The  white  polyethylene  monofilament  tail  strings  pass 
through and are knotted below a 3-mm plastic ball at the base of the 
stem. The ball helps reduce cervical perforation with expulsion. The 
copper IUD is approved by the FDA for up to 10 years of use, but a 
recent study suggests that it may be effective for at least 12 years. No 
pregnancies were reported before the eighth year of use.
The  progesterone-releasing  IUD  (Progestasert,  Alza 
Laboratories, Palo Alto, CA; acquired by Abbott Laboratories, North 
Chicago, IL in 1999) is a T-shaped device made of ethylene / vinyl 
acetate  copolymer.  The  frame  is  radiopaque.  The  stem  contains  a 
reservoir  of  39  mg of  progesterone  that  is  released  at  a  rate  of  65 
µg/day. The two arms are used only to stabilize the device. The device 
has two blue-black monofilament strings attached at a hole in the base 
of  the  stem.  The  progesterone-releasing  IUD  is  approved  for  12 
months of use in the United States.
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Selection of candidates
Product labeling indicates that the IUD user should be parous 
woman  with  no  history  of  PID  who  is  in  a  stable  mutually 
monogamous  relationship.  The  parous  woman  need  not  have 
completed her childbearing but must have demonstrated her fertility. It 
is estimated that more than 10 million American women fit all aspects 
of  this  patient  profile  and  have  no  contraindications  to  IUD  use; 
however,  many  more  millions  of  women  may  also  be  excellent 
candidates for IUD use.
Nulliparity  has  never  been  a  contraindication  to  IUD  use. 
Although is recognized that IUD insertion through a cervix that has not 
been previously dilated may be slightly more challenging, many parous 
women who have been electively delivered by cesarean section present 
the  same  challenges.  The  uterine  cavity  of  a  nulliparous  woman  is 
smaller. As a result, the expulsion and failure rates are slightly higher 
in women who have never borne children, but the IUD still provides 
excellent pregnancy protection for these women. The real concern with 
IUD use in nulliparous women who are not at risk for STDs is not 
strictly  medical  but  medicolegal.  Ten  percent  to  15% of  American 
26
couples  sustain  infertility  problems.  Placing  IUDs  in  women  with 
unproved fertility exposes the IUD, and potentially the provider, to the 
risk  of  charges  after  IUD  removal  that  the  IUD  caused  infertility. 
Careful  preinsertion  counseling  is  needed  to  explain  potential 
unrecognized infertility to nulliparous patients. 
27
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MECHANISMS OF ACTION
Copper Intrauterine Devices
Misguided concerns that the IUD works as an abortifacient have 
seriously limited IUD use by many women and have prevented many 
providers from offering IUDs. The evidence is clear that the IUD does 
not  work  as  a  postimplantation  abortifacient.  Segal  and  co-workers 
monitored  30  women  using  IUDs  by  measuring  serial  beta-human 
chorionic gonadotropin levels for 30 months and did not observe any 
changes in levels. In particulars, there was no evidence of an initial rise 
followed  by  an  abrupt  drop  in  levels  characteristic  of  pregnancy 
interruption. Wilcox and co-workers found one episode of a transient 
increase in 107 IUD cycles. Moreover, the failure of uterine washings 
to retrieve eggs in 56 IUD users in contrast to washings yielding eggs 
in  4 of  115 controls  undermines  the hypothesis  that  IUDs work by 
creating inflammatory endometrial changes that prevent implantation.
The  copper  IUD  is  a  functional  spermicide;  the  copper  ions 
released from the device interfere with sperm mobility  and create a 
foreign-body reaction that results in a spemicidal endometrium. Sperm 
counts in the cervical mucus are significantly lower in IUD users than 
they are in nonusers. Oviduct counts of sperm are vanishingly small in 
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IUD  users.  El-Habashi  and  Moyer  and  their  co-workers  reported 
finding  no  sperm  in  the  fallopian  tubes  of  30  women  with  IUDs. 
Microscopic studies demonstrate that the inflammatory changes in the 
endometrium  are  spermicidal.  Clusters  of  leukocytes  are  seen 
engulfing the sperm. Sagiroglu found that 2 to 16 hours after coitus, 
spermatozoa  were  phagocytized  in  the  endometrial  cavities  of  IUD 
users.  The  copper  ions  inhibit  sperm penetration  into  the  egg;  the 
acrosomal  enzymes  needed  to  dissolve  the  zona  pellucida  are  not 
activated in the presence of copper ions. 
30
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Efficacy
Because  IUDs require  little  patient  action  for  their  continued 
action,  the  typical  failure  rates  for  IUDs  closely  approximate  the 
failure rates associated with correct and consistent use; however, the 
effectiveness of the IUD varies by model. The copper IUD has a first-
year failure rate of 0.7% with typical use. Mulliparous women have 
slightly  higher failure  rates (0.8%) than parous women.  The copper 
IUD has  a  cumulative  10-year  typical  failure  rate  of  2.1% of  2.7T 
which  is  less  than  the  typical  first-year  failure  rate  for  oral 
contraceptives. The progesterone-releasing IUD has a first-year typical 
use failure rate of 2%. The Lippes Loop and  Safe-T-Coil IUDs have a 
first-year  failure  rate  of  3%,  but  current  users  of  these  IUDs  may 
experience  significantly  lower  pregnancy  rates  because  they  have 
successfully used their devices for so many years. Table 1 summarizes 
the first-year failure rates. 
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EFFECT OF CONTRACEPTIVE PREVALENCE ON TOTAL 
FERTILITY (DATA FROM 15 DEVELOPING COUNTRIES)
33
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Contraindications to Intrauterine Devices (IUDS)
 General 
• Pregnancy
• Acute unresolved cervicitis (current or within the last  3 
months)
• Pelvic  inflammatory  disease,  endometritis,  or  pelvic 
tunerculosis (current or within the last 3 months)
• Distorted uterine cavity
• Uterine or cervical carcinoma
• Unexplained vaginal bleeding
• Severe  immunocompromise  (e.g.  acquired 
immunodeficiency syndrome, chemotherapy)
• Multiple sexual partners of partner with multiple sexual 
partners
 IUD specific
• Copper IUD
 Uterine cavity <6 or >9 cm
 Copper allergy
 Wilson’s disease
35
 Severe anemia
 Menorrhagia
 Severe dysmenorrhea
• Progesterone-releasing IUD
 Uterine cavity <6 or >10 cm
 History of ectopic pregnancy
 Diabetes
36
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AIM OF STUDY
The  study  is  to  evaluate  IUDs  in  terms  of  contraceptive 
effectiveness,  rate  of  removal,  side  effects  and  complications  – 
Bleeding,  Perforation,  Expulsion  and infection.  All  are  measured  in 
(life  table  rates)  that  is  the  number  of  pregnancy or  removal  /  500 
women users after a specified length of IUD use that is twelve months. 
In our hospital the copper T 380 is used so it is taken for study. 
39
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METHODS AND MATERIAL
All  IUD  users  were  taken  up  for  study.  This  study  group 
includes  post  partum  IUD  insertion,  interval  IUD  insertion,  Post 
abortal  insertion and post  caeserean insertion.  Analysis  done in this 
different groups to find out expulsion rate, pregnancy rate and removal 
rate and the causes for removal were analysed.
Oral enquiry was conducted to the users attending O.P. to find 
out the type and time of insertion also regarding any complications. 
Then  bimanual  pelvic  examination  speculum  examination  done  to 
check  up  the  position  of  IUD  and  to  find  out  any  complication 
associated with it. 
41
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INSERTION ISSUES
Timing and Preparation for Insertion
The IUD can be inserted anytime in a woman’s cycle when she 
is not pregnant. White and co-workers demonstrate that expulsion rates 
for the first three postinsertion cycles were reduced by more than 30% 
when insertion was delayed until the end of menses. Theoretically, the 
optimal time for insertion is at the time of ovulation, when the cervical 
canal is maximally dilated and progesterone can quiet the myometrial 
contractions triggered by uterine manipulation. Insertion postpartum is 
best  delayed  until  the  uterus  is  completely  involuted  (usually,  4-6 
weeks after delivery) to reduce the risk of perforation and expulsion. 
Nevertheless,  international  work suggests  that  insertion immediately 
postpartum (10-20 minutes after delivery of the placenta) is associated 
with  low  risks  of  uterine  perforation  and  expulsion  and  may  be  a 
reasonable  alternative  for  women  who  have  limited  access  to  the 
medical  care  system.  Women  who  have  miscarriages  or  other 
pregnancy  terminations  in  the  first  trimester  are  candidates  for 
immediate IUD insertion unless there is evidence of infection. 
The  preparation  for  IUD insertion  is  straightforward.  Women 
generally benefit from taking NSAIDs 1 hour before the insertion. A 
small amount of lidocaine injected at the tenaculum site can reduce the 
discomfort associated with the placement of that instrument. A small 
cotton  swab  generously  soaked  in  20% Hurricane  lidocaine  can  be 
placed  into  the  cervical  canal  to  reduce  insertional  discomfort  and 
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vasovagal  reactions.  If  the  patient  has  significant  cervical  stenosis 
(requiring  cervical  dilation),  a  paracervical  block  may  be  needed. 
Careful cleansing of the ectocervix, the upper vagina, and the cervical 
canal is intended to reduce bacterial contamination with insertion. 
Insertion Complications
Vasovagal reactions occur in approximately 1% of women with 
cervical manipulation, particularly in women with significant cervical 
stenosis.  If  a patient is  known to be at increased risk for vasovagal 
reactions, appropriate equipment should be available for resuscitation, 
and  a  prophylactic  paracervical  block  should  be  placed.  When  a 
transient  vasovagal  reaction  develops  during  insertion,  supportive 
measures are generally adequate. 
Uterine perforation occurs once in every 770 to 1600 insertions. 
The  copper  IUD  is  associated  with  fever  perforations  than  the 
progesterone  releasing  IUD.  Rick  factors  for  uterine  perforation 
include  an  immobile  or  extremely  verted  uterus  and,  most 
significantly, an inexperienced inserter. Lactation does not increase the 
risk of perforation. Most perforations occur when the uterus is initially 
sounded. The sound is the first instrument introduced into the uterus. 
Postinsertion Instructions
The patient should be instructed to check the length of the string 
after  menses  each month  to  ensure that  the device is  still  in  place. 
Although the  risks  of  postinsertion  problems are  small,  the  woman 
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should  be advised  to  watch for  symptoms  consistent  with the three 
main IUD-related problems (pregnancy, expulsion, and infection) and 
to  return  for  further  professional  evaluation  should  any  develop.  A 
moderate increase in menstrual blood loss and cramping can occur in 
the first 2 to 3 months following insertion of the copper IUD.
Return to fertility
The  contraceptive  effects  of  the  IUD  are  rapidly  reversible, 
therefore, the IUD is very appropriate as an interval method to help 
couples space their pregnancies. Pregnancy rates following removal of 
the copper IUD have been reported in several studies. The median time 
to planned pregnancy is about 3 months. Younger women had more 
rapid and more complete (100%) return to fertility. After controlling 
for age at time of removal; the duration of use had no impact on the 
time of return to fertility. 
Newer devices
It is expected that the levonorgestrel IUD will become available 
in the United States within a year. Carrying the brand name Minera 
(Berlex Laboratories, Wayne, NJ), it will probably be approved for 5 
years  of  use.  The  device  is  a  T-shaped  polyethylene  frame  with  a 
cylinder  of  polydimethylsiloxane  /  levonorgestrel  molded  within  its 
stem that releases 20  µg of levonorgestrel per day. Worldwide trials 
have  shown that  the  first-year  typical  use  failure  rate  is  0.1%. The 
mechanisms of action are related to the local application of progestin 
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and are similar to the mechanisms of the progesterone-releasing IUD. 
The cervical mucus thickens and prevents the passage of sperm into 
the  upper  genital  tract.  The  inflammatory  changes  induced  by  the 
plastic frame also contribute to efficacy by acting as a spermicide. The 
progestin  suppresses  the  endometrium  and  occasionally  suppresses 
ovulation. The side effects with this device are also influenced by the 
progestin.  Menstrual  changes  are  noted  by  most  users.  Women 
generally experience heavier bleeding in the first cycle but are more 
likely  to  experience  oligomenorrhea,  spotting,  or  amenorrhea  in 
subsequent  cycles.  Although the progestin will  not reliably suppress 
ovulation,  it  can show the atresia  of  existing follicles;  therefore,  an 
increased  risk  of  functional  ovarian  cysts  in  associated  with  the 
levonorgestrel IUD. The circulatory levels of progestin are lower than 
with other progestin contraceptives, thus a few women may complain 
of bloating or breast tenderness with the levonorgestrel-releasing IUD. 
This IUD has many attractive feature. 
A frameless IUD (FlexiGard or Cu-Fix) is used in Scandinavia 
for nulliparous women with smaller endometrial cavities. It consists of 
six pledgets of copper with a surface area of 330 mm2 placed in tandem 
on a polypropylene string that is knotted at both ends. The knot at the 
top of the string is embedded into the myometrium at insertion, and the 
strings below the lower knot protrude through the cervix for ongoing 
monitoring. 
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QUESTIONNAIRE
When can a woman have a copper-bearing IUD inserted?
Having menstrual cycles
• She can have a copper-bearing IUD inserted at any time within 
the  first  12  days  after  the  start  of  menstrual  bleeding,  at  her 
convenience,  not  just  during  menstruation.  No  additional 
contraceptive protection is needed.
• She also can have the copper-bearing IUD inserted at any other 
time  during  the  menstrual  cycle,  at  her  convenience,  if  it  is 
reasonably  certain  that  she  is  not  pregnant.  No  additional 
contraceptive protection is needed.
Amenorrhoeic (non-postpartum)
• She can have copper-bearing IUD inserted at any time, if it can 
be  determined  that  she  is  not  pregnancy.  No  additional 
contraceptive protection is needed. 
Postpartums and breastfeeding (including post-caesarean section)
• If she is less than 49 hours postpartum, she can generally have a 
copper-bearing IUD inserted.
• If she is 4 or more weeks postpartum and amenorrhoeic, she can 
have a copper-bearing IUD inserted, if it is reasonably certain 
that she is not pregnant. No additional contraceptive protection 
is needed.
• If she is 4 or more weeks postpartums and her menstrual cycles 
have returned, she can have a copper-bearing IUD inserted as 
advised for other women having menstrual cycles.
Postpartum  and  non-breastfeeding  (including  post-caesarean 
section)
• If she is less than 48 hours postpartum, she can generally have a 
copper-bearing IUD inserted.
• If she is 4 or more weeks postpartum and amenorrhoeic, she can 
have a copper-bearing IUD inserted, if it can be determined that 
she  is  not  pregnant.  No additional  contraceptive  protection  is 
needed.
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• If she is 4 or more weeks postpartum and her menstrual cycles 
have returned, she can have a copper-bearing IUD inserted as 
advised for other women having menstrual cycles.
Postabortion
• If  she  had  a  first-trimester  abortion,  she  can  have  a  copper-
bearing IUD inserted immediately postabortion.
• If she had a second-trimester abortion, she can generally have a 
copper-bearing IUD inserted immediately postabortion
Should  prophylactic  antibiotics  be  provided  for  copper-bearing 
IUD insertion?
Routine copper-bearing IUD insertion
• Prophylactic  antibiotics  are  generally  not  recommended  for 
copper-bearing  IUD  insertion.  In  settings  of  both  high 
prevalence of cervical gonococcal and chlamydial infections and 
limited  sexually  transmitted  infection  (STI)  screening,  such 
prophylaxis may be considered.
• Counsel the copper-bearing IUD user to watch for symptoms of 
pelvic  inflammatory  disease  (PID),  especially  during  the  first 
month.
Comments
• The  expert  Working  Group  determined  that  prophylactic 
antibiotics  for  copper-bearing  IUD  insertion  provide  little,  if 
any, benefit for women at low risk for STIs.
• This recommendation applies  to healthy women;  women with 
health  conditions  (e.g.  cardiac  valve  disorders)  that  warrant 
antibiotic  prophylaxis  for  invasive  procedures  may  also  need 
antibiotic prophylaxis for copper-bearing IUD insertion.
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ANALYSIS
Time of insertion 
Puerperal Post caeserean Interval Post abortal
200 50 200 50
40% 10% 40% 10%
Age wise 
15-19 years 20-24 years 25-29 years 30-34 
years
35-39 years
110 260 105 20 5
22.05% 51.88% 20.39% 4.77% 0.91%
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Para wise 
I II III IV & V
295 140 43 22
59.14% 28.37% 8.30% 4.19%
Socio Economic Wise 
I II III IV
139 115 45 273
26.67% 9.77% 9.77% 53.79%
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Educational Wise 
Below VII Std. VII to SSLC Above SSLC
248 247 5
49.88% 49.40% 0.72%
Total No. of Cases – 500
No %
1. No Complaints 60 35
2. Menorrhagia 32 16
3. Metrorrhagia 11 7
4 Spotting 8 4
5. Dysmenorrhoea 10 5
6. White Discharge 34 17
7. Back Ache 37 32
55
COMPLAINTS WITH  TIME OF INSERTION
L.S.C.S. Puerperal Post Abortal Interval
No % No % No % No %
1. Menorrhagia 2 4 8 4 20 40 50 25
2. Metrorrhagia 10 20 25 12.5
3. Spotting 5 10 15 7.5
4. Dysmenorrhoea 1 2 5 2.5 5 10 14 7.0
5. White Discharge 2 4 4 2 19 38 60 30
6. Back Ache 2 4 18 9 20 40 120 60
7. Pain Lower 
Abdomen
2 4 8 4 15 30 25 12.5
8. Cervicitis 1 2 8 4 15 30 26 13
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DISCUSSION
From June 2005 to July 2006.  500 cases were taken for study. 
Out of this 200 were puerperal insertion forming 40%. 50 were post 
caeserean insertion forming 10%. 200 interval insertion forming 40% 
and 50 were post abortal insertion forming 10%.
In our series this users were analysed according to agewise 110 
were between 15-19 years forming 22.05%, 260 were between 20-24 
years forming 51.88%, 105 were between 25-29 years forming 20.39% 
20 were between age of 30 to 34 years forming 4.77%, 5 were between 
31-35 years forming 0.91%.
In our series the users were analysed parawise 295 were para I 
forming 59.14%, 140 were para II forming 28.37%, 43 were para III 
forming 8.30% and 22 were para IV & V foming 4.19% those who are 
not willing for sterlisation Cu-T was inserted to para–III or more.
In  our  series  the  users  were  analysed  according  to  socio 
economic group 139 were socio economic group I forming 26.67%, 45 
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were  SE  Group  II  forming  9.77%,  45  were  SE  Group  III  forming 
9.77% and 273 were SE Group IV & V forming 53.79%. 
In our series the users were analysed education wise :
248 were below VII Std forming 49.88%
247 were VII to SSLC forming 49.40%
5 were above SSLC forming 0.72%
Follow up was done in selected number of IUD users in each 
group at  random and  100 users  were  followed,  40  were  from post 
placental  group,  10  were  post  caeserean Group,  10  were  from post 
abortal  group and 40 were  from interval  IUD users.  Complications 
were analysed followed after 1 month, 3 month, 6 month, 9 months, 
and after one year.
Out  of  this  100  users,  9  months  and  after  one  year.  35% 
Menorrhagia was found in 80 users forming 16% Metrorrhagia was 
found in 35 forming 7%.
Spotting was present  in users 20 forming 4% Dysmenorrhoea 
was found in 25 users forming 5% white discharge was present in 85 
users  forming  17%.  These  patients  were  examined  for  T.V.  and 
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Moniliasis  20  had  T.V.  infection  forming  4%  and  the  same  were 
treated,  Backache  was  found in  160 users  forming  32% pain lower 
abdomen was found in 50 users forming 10%.  These complaints were 
analysed with the time of insertion. 
L.S.C.S. GROUP 
• Menorrhagia  was  found  in  2  users  forming  4%. 
Dysmenorrhoea was found in 1 users forming 2.
• White discharge was found in 2 users forming 4%
• Back ache was found in 2 users forming 4%
• Pain lower abdomen was found in 2 users forming 4%
PUERPERAL GROUP
• Menorrhagia was found in 8 users forming 4%
• Dysmenorrhoea was found in 5 users forming 2.5%
• White discharge was found in 4 users forming 2%
• Back ache was found in 18 users forming 9%
• Pain lower abdomen was found in 8 users forming 4%
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POST ABORTAL GROUP
• Menorrhagia was found in 20 users forming 40%
• Dysmenorrhoea was found in 5 users forming 10%
• White discharge was found in 19 users forming 38%
• Back ache was found in 20 users forming 40%
• Pain lower abdomen was found in 15 users forming 30%
INTERVAL GROUP
• Menorrhagia was found in 50 users forming 25%
• Dysmenorrhoea was found in 15 users forming 7%
• White discharge was found in 60 users forming 30%
• Back ache was found in 120 users forming 60%
• Pain lower abdomen was found in 25 users forming 12.5%
Complaints were analysed with duration of IUCD after 1 month, 
3 months, 6 months, 9 motnhs and 1 year. The complaints were same 
after  1  month  and  3  months  and  after  that  they  are  decreased 
Menorrhagia was decreased from 16% to 3% at the end of 1 year. 
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Metrorrhagia was reduced from 7 to 2% spotting was reduced 
from  4  to  1%  Dysmenorrhoea  was  reduced  from  5  to  3%,  White 
discharge was decreased from 17 to 3%. Back ache was reduced from 
32 to 12% pain lower abdomen was reduced from 10 to 3%.
In  this  users  expulsion  rate  was  analysed  in  each  group. 
Expulsion rate was very high in puerperal group forming 60% cases. 
The reasons for it may due to involution of uterus and patulous cervix. 
From the interval group 2 expelled the Cu-T forming 1%. From the 
post abortal group 1 expelled forming 2%. In post Caeserean group the 
insertion was done on the day of discharge i.e. 10 to 14 days. In this 
group 1 expelled the Cu. T. forming 2%.
Removal of IUD was analysed in our series. 50 users came for 
removal of Cu.T. Menstrual disorder was found in 20 forming 4% pain 
in lower abdomen was found in 20 forming 4% 10 users were planning 
for further pregnancy forming 2%.
No pregnancy was met in any of our series, no perforation and 
dislocation was found in any of our series. Out of 16 expulsion cases, 
14 cases had seen the expelled CUT.  In 2 cases X-rays were taken 
CUT was not found in the uterine cavity or in the peritoneal cavity, the 
patients were reassured.
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SUMMARY AND CONCLUSION
Summary
Out of these 500 users that  were followed for one year,  200 
were  puerperal  group,  50  were  post  caeserean  group,  50  were  post 
abortal group, 200 were Interval group. Out of these 20 no complaints 
were found in 60 users forming 35%. Menorrhagia was found in 35 
users forming 16%. Metrorrhagia was found in 14 users forming 7%. 
Spotting was found in 8 users forming 4%. Dysmenorrhoea was found 
in  10  users  forming  5%.  White  discharge  was  found  in  34  users 
forming 17%. Back ache was found in 37 users forming 32%. Pain 
lower abdomen was found in 20 users forming 10%. The Menstrual 
disorder and other complaints were reduced in due course of use. 
The complaints were analysed with time of insertion. In L.S.C.S. 
group  Menorrhagia  forming  4%.  Dysmenorrhoea  form  2%,  white 
discharge form 4%, back-ache form 4%. Pain lower abdomen forms 
4%, cervicitis forms 2%. In puerperal group Menorrhagia forms 4%, 
Dysmenorrhoea  forms  2.5%  white  discharge  forms  2%,  back-ache 
forms  9%  pain  lower  abdomen  forms  4%.   In  post  abortal  group 
Menorrhagia  forms  40%,  Metrorrhagia  forms  20%  spotting  forms 
64
10%, Dysmenorrhoea forms 10%, white discharge forms 38% back-
ache  forms  40%,  pain  lower  abdomen  forms  30%,  cervicitis  forms 
30%. In Interval group Menorrhagia forms 25%, metrorrhagia forms 
12.5% spotting forms 7.5% Dysmenorrhoea forms 7% white discharge 
forms 30% back-ache forms 60%, pain lower abdomen forms 12.5% 
and cervicitis form 13%.
The  expulsion  rate  was  analysed  in  each  group.  In  puerperal 
group the expulsion rate was very high. 12 users expelled the Cut from 
6%. From the interval group 2 expelled the cut forming 1%. From the 
post abortal group 1 expelled the cut forming 2%. In post caeserean 
group the  insertion  was  done  on  12th –  14th week.  In  this  group  1 
expelled the Cu T forming 2%.
The cause for  removal  is  analysed.  5 users  came for removal 
forming  10%.  CuT was  removed  in  3  users  for  menstrual  disorder 
forming 4%. For pain lower abdomen CuT removed in 3 users forming 
4%.  2  users  were  planned  for  further  pregnancy  forming  2%.  The 
continuation rate was 85%. 
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Perforation, pregnancy and ectopic pregnancy were not found in 
our series.  The infection is minimized by aseptic precaution, PID is 
minimized by not inserting the CuT in persons suffering from STD.
Missing  thread was  seen  in 2 in our  series.   X-ray and USG 
taken CUT was not  found in  uterine  cavity  or  in  peritoneal  cavity. 
These 2 cases were considered under expulsion group.
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CONCLUSION
LSCS Group 
Menorrhagia, Dysmenorrhoea, back ache are more common.
Puerperal group
Back ache (9%), Lower abdominal pain (8%) Cervicitis (8%) are 
predominant.
Post abortal group 
Menorrhagia  (40%),  Back  ache  (40%)  white  discharge  are 
common complaints during the course of follow up.
Interval group
Menorrhagia,  (25%),  white  discharge  are  seen  but  in  less 
number of cases.
Expulsion rate 
Expulsion rate is more in puerperal group.
Less common in Interval and post abortal group.
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Removal group
CuT was removed for menstrual disorder in 4% of cases.
For lower abdominal pain CuT removed fro 2 users.
2 users were planned for further pregnancy.
So continuation rate was 85%. CuT has minimal morbidity and 
mortality.
Expulsion rate was minimal when it was inserted in post-abortal 
and interval group by well trained person. 
White discharge can be minimized in Interval group by inserting 
CuT under antibiotic cover.
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PROFORMA FOR ORAL ENQUIRY
I. 1. Name of the User :
2. Age :
3. O.P. No. / I.P. No. :
4. Address :
5. Religion :
6. Socio Economic Status :
7. Education Status :
II. Personal History :
III. Family History :
IV. Menstrual History :
1. Age of Menarche :
2. Cycles & Flow :
3. Dysmenorrhoea :
4. LMP :
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V. Obstetrical History :
a) Age of Marriage :
b) No. of deliveries & :
age of Children
c) No. of abortion :
d) LCB :
e) Last Abortion :
VI IUCD
1. Time of insertion :
a. Post – Abortal
b. Post – Placental
c. Interval
d. Post-Caeserean
VII General Examination
VIII Breast Examination
IX Abdominal Examination
X Speculam Examination
XI Bimanual Pelvic Examination
XII Vaginal Smear Examination for T.V. 6 Moniliasis
71
XIII Follow-up 1st Month 3 6 9 1yr
1. Perforation
2. Menorrhagia
3. metrorrhagia
4. Dysmenorrhoea
5. Spotting
6. back-ache
7. lower abdominal pain
8. white discharge
9. pregnancy with CuT insitu
10. Cervicitis
11. Expulsion
12. Cause of removal
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1. Padma 23 IV P1  
2. Noorani 25 I P1 
3. Padma 25 IV P1  
4. Thara 33 IV P4  
5. Gomathi 23 II P1 
6. Kamatchi 24 IV P1   
7. Indira 42 III P4 
8. Valli 24 IV P1   
9. Selvaranai 40 II P1  
10. Nalini 22 IV P1  
11. Rajalakshmi 25 IV P1  
12. Revathi 24 I P1  
13. Sindya 25 IV P1 
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14. Sudha 20 IV P1  
15. Nirmala 29 III P3  
16. Deepa 20 IV P1  
17. Indira 21 II P1  
18. Shabran Banu 23 IV P1  
19. Nirmala 24 IV P1  
20. Bhavanai 21 IV P1  
21. Ashma 21 IV P1 
22. Sasikala 22 IV P1  
23. Rajam 24 IV P1  
24. Pushpa 23 IV P1  
25. Krishnaveni 28 IV P4  
26. Saradha 24 IV P1 
27. Nirmala 26 IV P1  
28. Kumari 26 IV P1 
29. Uma 28 II P3  
30. Nagarathinam 26 IV P1  
31. Sangeetha 27 IV P1 
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32. Geetha 25 IV P1  
33. Vahitha 24 IV P1  
34. Nandhini 28 IV P1  
35. Seethalakshmi 29 I P1 
36. Sundari 25 IV P1  
37. Chitra 29 III P1  
38. Sabhana 27 II P1  
39. Nalini 26 IV P1  
40. Ramsan Begum 31 IV P1  
41. Meera 30 IV P1  
42. Muthulakshmi 30 III P1 
43. Indira 18 IV P1  
44. Sridevi 28 IV P1  
45. Nalini 24 IV P1 
46. Kavitha 26 I P1  
47. Devi 27 IV P1  
48. Visitha 27 IV P1  
49. Nirmala 25 IV P1 
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50. Anandhi 30 IV P1 
51. Amutha 23 IV P1 
52. Vijaya 29 II P1  
53. Bharathi 29 IV P1  
54. Sridevi 30 IV P3  
55. Kalavathy 25 II P1  
56. Lakshmi 28 IV P1 
57. Viji 31 IV P1  
58. Sathya 20 III P1  
59. Santhanalakshmi 21 I P1  
60. Vimala 26 IV P1 
61. Uma 30 IV P1 
62. Malliga 24 IV P1   
63. Indumathi 27 II P1  
64. Priya 25 IV P1 
65. Sumathy 19 IV P1  
66. Thangalatha 22 II P1  
67. Vimala 28 IV P1 
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68. Selvi 27 IV P1  
69. Kavitha 26 II P1  
70. Bhuvana 26 IV P1  
71. Vatchala 28 IV P1  
72. Suganya 26 IV P1  
73. Jayanthi 32 IV P4  
74. Santhi 34 II P1  
75. Tamilarasi 30 IV P1  
76. Poongodi 20 IV P1  
77. Ambiga 18 IV P1 
78. Subashini 22 IV P1 
79. Rajalakshmi 36 I P1 
80. Priya 32 IV P4  
81. Padmavathi 26 IV P1  
82. Bhavani 22 IV P1 
83. Varalakshmi 30 I P1  
84. Parvathi 27 IV P1  
85. Geetha 22 IV P1  
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86. Revathi 24 II P1  
87. Kalai 20 IV P1  
88. Mohana 22 IV P1  
89. Sundari 32 IV P1  
90. Mullai 22 III P1 
91. Soundarya 18 IV P1 
92. Saroja 22 IV P1  
93. Shalini 24 IV P1  
94. Reena 26 IV P1 
95. Anitha 24 IV P1  
96. Jaya 26 I P1 
97. Rajaeswari 18 IV P1 
98. Thulasi 22 IV P1  
99. Mahalakshmi 24 IV P1 
100
.
Rekha 18 IV P1  
101
.
Roja 26 IV P1 
102 Manjula 20 IV P1  
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.103
.
Suhasini 26 IV P1  
104
.
Dhanalakshmi 22 IV P1  
105
.
Megala 20 IV P1  
106
.
Kathirmathi 28 II P1  
107
.
Usha 26 IV P1  
108
.
Jeeva 22 IV P1 
109
.
Girija 27 IV P1 
110
.
Indirani 28 IV P1  
111
.
Soniya 18 IV P1 
112
.
Meena 19 IV P1 
113 Dhesam 26 IV P1  
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.114
.
Abirami 20 II P3 
115
.
Vasantha 28 IV P1  
116
.
Samundeeswari 26 IV P1  
117
.
Sasikala 26 IV P1  
118
.
Muthulakshmi 20 III P1 
119
.
Malathi 28 IV P1  
120
.
Nirmala 26 IV P1 
121
.
Vimalarani 26 III P1  
122
.
Mullai 28 IV P1  
123
.
Kousalya 26 IV P1 
124 Maya 28 IV P1  
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.125
.
Mythili 22 IV P1  
126
.
Subhasini 26 IV P2 
127
.
Ramya 22 IV P1  
128
.
Chandra 26 IV P1  
129
.
Yogalakshmi 22 III P1 
130
.
Sowmiya 22 IV P1  
131
.
Athilakshmi 26 IV P1  
132
.
Rubini 18 IV P1  
133
.
Rupa 26 IV P1  
134
.
Poongodi 22 III P1 
135 Ambiga 26 IV P1  
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.136
.
Nalini 30 IV P1  
137
.
Monika 18 II P1  
138
.
Lakshmi 26 IV P1  
139
.
Parvathi 20 IV P1 
140
.
Divya 22 IV P1  
141
.
Vijayalakshmi 26 IV P1 
142
.
Sandya 20 III P1  
143
.
Kala 26 IV P1 
144
.
Sathya 28 II P1  
145
.
Rani 18 IV P1  
146 Radhika 20 IV P2  
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.147
.
Kalavathi 20 III P1  
148
.
Rukmani 26 IV P1  
149
.
Jayanthi 26 IV P1 
150
.
Rohini 28 IV P1  
151
.
Surya 26 IV P1 
152
.
Pooja 32 IV P1  
153
.
Thamarai 24 III P1 
154
.
Selvi 18 IV P1 
155
.
Nirmala 19 IV P1  
156
.
Suganya 22 IV P1 
157 Radha 20 IV P1  
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.158
.
Roshini 26 III P1  
159
.
Subashini 21 IV P1  
160
.
Pavithra 24 IV P1 
161
.
Govindammal 30 II P1 
162
.
Vinitha 28 IV P1  
163
.
Jothi 18 IV P1 
164
.
Bhuvana 18 IV P1  
165
.
Sorna 20 III P1 
166
.
Dhatchayani 26 IV P1  
167
.
Banu 28 IV P2 
168 Sophiya 28 IV P1  
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.169
.
Sharbanu 30 IV P1 
170
.
Fathima 19 III P1 
171
.
Kalaiarasi 24 IV P1  
172
.
Samundi 22 IV P1  
173
.
Parameswari 22 IV P1  
174
.
Kamini 28 IV P1  
175
.
Raji 26 III P1 
176
.
Priya 21 IV P1  
177
.
Divyasri 30 IV P1 
178
.
Kavitha 19 IV P1  
179 Jayalakshmi 22 II P1 
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.180
.
Sudha 24 IV P1 
181
.
Jayasri 26 IV P1  
182
.
Gunalakshmi 28 IV P1  
183
.
Nirmala 26 III P1  
184
.
Sumathi 20 IV P1 
185
.
Dharshini 22 IV P1  
186
.
Roja 18 IV P1  
187
.
Malini 19 IV P2 
188
.
Soniya 22 IV P1  
189
.
Kuppulakshmi 26 IV P1  
190 Vanam 30 IV P1 
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.191
.
Pachyamma 28 IV P1  
192
.
Shoba 29 II P1  
193
.
Durga 22 IV P1  
194
.
Subashini 30 IV P1  
195
.
Sathya 28 IV P1  
196
.
Gayathiri 26 III P1  
197
.
Bharathi 28 IV P2  
198
.
Pavithra 29 IV P1  
199
.
Revathi 25 IV P1 
200
.
Keerthana 24 IV P1  
201 Indira 26 IV P1  
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.202
.
Ambiga 28 IV P1 
203
.
Soundarya 18 IV P1 
204
.
Rajaeswari 20 IV P1 
205
.
Rekha 20 IV P1  
206
.
Soniya 26 IV P1 
207
.
Rubini 26 IV P1  
208
.
Monika 28 II P1  
209
.
Rani 26 IV P1  
210
.
Selvi 32 IV P1 
211
.
Jothi 24 IV P1 
212 Bhuvana 18 IV P1  
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.213
.
Roja 19 IV P1  
214
.
Sumathy 22 IV P1  
215
.
Meena 20 IV P1 
216
.
Nirmala 26 IV P1  
217
.
Fathima 21 III P1 
218
.
Kavitha 24 IV P1  
219
.
Malini 30 IV P2 
220
.
Sudha 28 IV P1  
221
.
Deepa 18 IV P1  
222
.
Sathya 22 III P1  
223 Poongodi 18 IV P1  
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.224
.
Kalai 19 IV P1  
225
.
Manjula 22 IV P1  
226
.
Megala 26 IV P1  
227
.
Abirami 30 II P3 
228
.
Muthulakshmi 28 III P1 
229
.
Parvathi 29 IV P1 
230
.
Sandya 22 III P1  
231
.
Radhika 30 IV P2  
232
.
Kalavathi 28 III P1  
233
.
Radha 26 IV P1  
234 Sorna 28 III P1 
95
.235
.
Sumathi 29 IV P1 
236
.
Indira 25 II P1  
237
.
Bhavanai 24 IV P1  
238
.
Ashma 26 IV P1 
239
.
Santhanalakshmi 28 I P1  
240
.
Subashini 18 IV P1  
241
.
Priya 20 IV P1  
242
.
Nalini 20 IV P1  
243
.
Sasikala 26 IV P1  
244
.
Thangalatha 26 II P1  
245 Subashini 28 IV P1 
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.246
.
Bhavani 26 IV P1 
247
.
Geetha 32 IV P1  
248
.
Mohana 28 IV P1  
249
.
Mullai 22 III P1 
250
.
Saroja 26 IV P1  
251
.
Thulasi 22 IV P1  
252
.
Dhanalakshmi 26 IV P1  
253
.
Jeeva 22 IV P1 
254
.
Mythili 22 IV P1  
255
.
Ramya 26 IV P1  
256 Yogalakshmi 18 III P1 
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.257
.
Sowmiya 26 IV P1  
258
.
Poongodi 22 III P1 
259
.
Divya 26 IV P1  
260
.
Suganya 20 IV P1 
261
.
Samundi 26 IV P1  
262
.
Parameswari 22 IV P1  
263
.
Jayalakshmi 20 II P1 
264
.
Dharshini 25 IV P1  
265
.
Soniya 24 IV P1  
266
.
Durga 28 IV P1  
267 Padma 29 IV P1  
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.268
.
Gomathi 25 II P1 
269
.
Shabran Banu 29 IV P1  
270
.
Pushpa 27 IV P1  
271
.
Amutha 26 IV P1 
272
.
Mahalakshmi 31 IV P1 
273
.
Kamatchi 30 IV P1   
274
.
Valli 30 IV P1   
275
.
Revathi 18 I P1  
276
.
Nirmala 28 IV P1  
277
.
Rajam 24 IV P1  
278 Saradha 26 IV P1 
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.279
.
Vahitha 27 IV P1  
280
.
Nalini 27 IV P1 
281
.
Malliga 25 IV P1   
282
.
Revathi 30 II P1  
283
.
Shalini 23 IV P1  
284
.
Anitha 29 IV P1  
285
.
Thamarai 29 III P1 
286
.
Pavithra 30 IV P1 
287
.
Kalaiarasi 25 IV P1  
288
.
Sudha 28 IV P1 
289 Keerthana 31 IV P1  
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.290
.
Noorani 20 I P1 
291
.
Padma 21 IV P1  
292
.
Rajalakshmi 25 IV P1  
293
.
Sindya 30 IV P1 
294
.
Geetha 18 IV P1  
295
.
Sundari 21 IV P1  
296
.
Nirmala 25 IV P1 
297
.
Kalavathy 23 II P1  
298
.
Priya 20 IV P1 
299
.
Revathi 25 IV P1 
300 Nirmala 27 IV P1  
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.301
.
Kumari 26 IV P1 
302
.
Nagarathinam 31 IV P1  
303
.
Nalini 30 IV P1  
304
.
Kavitha 30 I P1  
305
.
Vimala 18 IV P1 
306
.
Kavitha 28 II P1  
307
.
Bhuvana 24 IV P1  
308
.
Suganya 26 IV P1  
309
.
Padmavathi 27 IV P1  
310
.
Reena 27 IV P1 
311 Jaya 25 I P1 
102
.312
.
Roja 30 IV P1 
313
.
Suhasini 23 IV P1  
314
.
Usha 29 IV P1  
315
.
Dhesam 29 IV P1  
316
.
Samundeeswari 30 IV P1  
317
.
Sasikala 25 IV P1  
318
.
Nirmala 28 IV P1 
319
.
Vimalarani 31 III P1  
320
.
Kousalya 20 IV P1 
321
.
Subhasini 18 IV P2 
322 Chandra 23 IV P1  
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.323
.
Athilakshmi 29 IV P1  
324
.
Rupa 21 IV P1  
325
.
Ambiga 26 IV P1  
326
.
Lakshmi 27 IV P1  
327
.
Vijayalakshmi 23 IV P1 
328
.
Kala 27 IV P1 
329
.
Rukmani 20 IV P1  
330
.
Jayanthi 18 IV P1 
331
.
Surya 29 IV P1 
332
.
Roshini 21 III P1  
333 Dhatchayani 28 IV P1  
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.334
.
Raji 30 III P1 
335
.
Jayasri 27 IV P1  
336
.
Nirmala 25 III P1  
337
.
Kuppulakshmi 28 IV P1  
338
.
Gayathiri 27 III P1  
339
.
Sangeetha 29 IV P1 
340
.
Sabhana 21 II P1  
341
.
Devi 28 IV P1  
342
.
Visitha 26 IV P1  
343
.
Indumathi 24 II P1  
344 Selvi 23 IV P1  
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.345
.
Parvathi 25 IV P1  
346
.
Girija 21 IV P1 
347
.
Krishnaveni 26 IV P4  
348
.
Uma 22 II P3  
349
.
Nandhini 20 IV P1  
350
.
Sridevi 19 IV P1  
351
.
Lakshmi 27 IV P1 
352
.
Vimala 21 IV P1 
353
.
Vatchala 25 IV P1  
354
.
Kathirmathi 21 II P1  
355 Indirani 29 IV P1  
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.356
.
Vasantha 21 IV P1  
357
.
Malathi 26 IV P1  
358
.
Mullai 28 IV P1  
359
.
Maya 25 IV P1  
360
.
Sathya 22 II P1  
321
.
Rohini 25 IV P1  
362
.
Vinitha 24 IV P1  
363
.
Banu 25 IV P2 
364
.
Sophiya 20 IV P1  
365
.
Kamini 29 IV P1  
366 Gunalakshmi 20 IV P1  
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.367
.
Pachyamma 21 IV P1  
368
.
Sathya 23 IV P1  
369
.
Bharathi 24 IV P2  
370
.
Nirmala 21 III P3  
371
.
Seethalakshmi 21 I P1 
372
.
Chitra 22 III P1  
373
.
Vijaya 24 II P1  
374
.
Bharathi 23 IV P1  
375
.
Shoba 28 II P1  
376
.
Pavithra 24 IV P1  
377 Meera 26 IV P1  
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.378
.
Muthulakshmi 26 III P1 
379
.
Anandhi 28 IV P1 
380
.
Sridevi 26 IV P3  
381
.
Uma 27 IV P1 
382
.
Tamilarasi 25 IV P1  
383
.
Varalakshmi 24 I P1  
384
.
Nalini 22 IV P1  
385
.
Govindammal 25 II P1 
386
.
Sharbanu 24 IV P1 
387
.
Divyasri 25 IV P1 
388 Vanam 20 IV P1 
109
.389
.
Subashini 29 IV P1  
390
.
Ramsan Begum 20 IV P1  
391
.
Viji 21 IV P1  
392
.
Jayanthi 23 IV P4  
393
.
Priya 24 IV P4  
394
.
Sundari 21 IV P1  
395
.
Pooja 21 IV P1  
396
.
Thara 22 IV P4  
397
.
Santhi 24 II P1  
398
.
Rajalakshmi 23 I P1 
399 Selvaranai 28 II P1  
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.400
.
Indira 24 III P4 
401
.
Santhanalakshmi 21 IV P1  
402
.
Rajalakshmi 36 III P1 
403
.
Varalakshmi 30 IV P1  
404
.
Jaya 26 IV P1 
405
.
Vijaya 29 IV P1  
406
.
Kalavathy 25 IV P1  
407
.
Indumathi 27 IV P1  
408
.
Thangalatha 22 IV P1  
409
.
Kavitha 26 III P1  
410 Santhi 34 IV P1  
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.411
.
Revathi 24 III P1  
412
.
Kathirmathi 28 IV P1  
413
.
Abirami 20 IV P3 
414
.
Monika 18 IV P1  
415
.
Sathya 28 IV P1  
416
.
Sathya 20 II P1  
417
.
Mullai 22 IV P1 
418
.
Muthulakshmi 20 IV P1 
419
.
Vimalarani 26 IV P1  
420
.
Yogalakshmi 22 IV P1 
421 Poongodi 22 II P1 
.422
.
Sandya 20 IV P1  
423
.
Kalavathi 20 IV P1  
424
.
Anandhi 30 IV P1 
425
.
Amutha 23 II P1 
426
.
Bharathi 29 IV P1  
427
.
Sridevi 30 IV P3  
428
.
Lakshmi 28 IV P1 
429
.
Viji 31 IV P1  
430
.
Vimala 26 IV P1 
431
.
Uma 30 I P1 
432 Malliga 24 IV P1   
113
.433
.
Priya 25 III P1 
434
.
Sumathy 19 II P1  
435
.
Vimala 28 IV P1 
436
.
Selvi 27 IV P1  
437
.
Bhuvana 26 IV P1  
438
.
Vatchala 28 III P1  
439
.
Suganya 26 IV P1  
440
.
Jayanthi 32 IV P4  
441
.
Tamilarasi 30 IV P1  
442
.
Poongodi 20 IV P1  
443 Ambiga 18 IV P1 
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.444
.
Subashini 22 IV P1 
445
.
Priya 32 IV P4  
446
.
Padmavathi 26 I P1  
447
.
Bhavani 22 IV P1 
448
.
Parvathi 27 IV P1  
449
.
Geetha 22 IV P1  
450
.
Kalai 20 IV P1  
451
.
Mohana 22 IV P1  
452
.
Sundari 32 IV P1  
453
.
Soundarya 18 IV P1 
454 Saroja 22 IV P1  
115
.455
.
Shalini 24 IV P1  
456
.
Reena 26 II P1 
457
.
Anitha 24 IV P1  
458
.
Rajaeswari 18 IV P1 
459
.
Thulasi 22 IV P1  
460
.
Mahalakshmi 24 IV P1 
461
.
Rekha 18 IV P1  
462
.
Roja 26 IV P1 
463
.
Manjula 20 IV P1  
464
.
Suhasini 26 II P1  
465 Dhanalakshmi 22 IV P1  
116
.466
.
Megala 20 IV P1  
467
.
Usha 26 IV P1  
468
.
Jeeva 22 III P1 
469
.
Girija 27 IV P1 
470
.
Indirani 28 IV P1  
471
.
Soniya 18 III P1 
472
.
Meena 19 IV P1 
473
.
Dhesam 26 IV P1  
474
.
Vasantha 28 IV P1  
475
.
Samundeeswari 26 IV P1  
476 Sasikala 26 IV P1  
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.477
.
Malathi 28 IV P1  
478
.
Nirmala 26 IV P1 
479
.
Mullai 28 III P1  
480
.
Kousalya 26 IV P1 
481
.
Maya 28 IV P1  
482
.
Mythili 22 IV P1  
483
.
Subhasini 26 IV P2 
484
.
Ramya 22 III P1  
485
.
Chandra 26 IV P1  
486
.
Sowmiya 22 IV P1  
487 Athilakshmi 26 II P1  
118
.488
.
Rubini 18 III P1  
489
.
Rupa 26 IV P1  
490
.
Ambiga 26 IV P1  
491
.
Nalini 30 II P1  
492
.
Lakshmi 26 IV P1  
493
.
Parvathi 20 IV P1 
494
.
Divya 22 IV P1  
495
.
Vijayalakshmi 26 IV P1 
496
.
Kala 26 III P1 
497
.
Rani 18 IV P1  
498 Radhika 20 II P2  
119
.499
.
Rukmani 26 IV P1  
500
.
Jayanthi 26 IV P1 
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